▶ 調査レポート

世界のアンチトロンビン市場2022年-2027年:成長・動向・新型コロナの影響・市場予測

• 英文タイトル:Antithrombin Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Antithrombin Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)「世界のアンチトロンビン市場2022年-2027年:成長・動向・新型コロナの影響・市場予測」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2203A792
• 出版社/出版日:Mordor Intelligence / 2022年1月
• レポート形態:英文、PDF、109ページ
• 納品方法:Eメール(受注後2-3営業日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥703,000 (USD4,750)▷ お問い合わせ
  Site Licence¥962,000 (USD6,500)▷ お問い合わせ
  Corporate License¥1,295,000 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Mordor Intelligence社の本調査資料では、世界のアンチトロンビン市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、用途別(治療、診断、研究、その他)分析、由来別(ヒト、組換え山羊乳、その他)分析、種類別(抗凝固剤、抗血小板剤、血栓溶解剤)分析、経路別(経口、非経口)分析、地域別(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)分析、競争状況、市場機会・将来の傾向などの項目を掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・市場動向
・世界のアンチトロンビン市場規模:用途別(治療、診断、研究、その他)
・世界のアンチトロンビン市場規模:由来別(ヒト、組換え山羊乳、その他)
・世界のアンチトロンビン市場規模:種類別(抗凝固剤、抗血小板剤、血栓溶解剤)
・世界のアンチトロンビン市場規模:経路別(経口、非経口)
・世界のアンチトロンビン市場規模:地域別(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)
・競争状況(CSL Limited、Grifols S.A、Takeda Pharmaceutical Company Limited、...)
・市場機会・将来の傾向

The growing incidence of conditions (like sepsis, congenital antithrombin deficiency, disseminated intravascular coagulation (DIC), extracorporeal membrane oxygenation (ECMO)), and elevated open-heart surgeries are likely to increase the growth of the global antithrombin market. Thrombotic diseases require a long term treatment of antithrombin drugs; this contributes to the increase in production and sales of Antithrombin. The increased usage of rapid diagnostic tests, which in turn use antithrombin, boosts the demand of the protein in the diagnostic field. The increased use of biologics and the high cost of antithrombin are the two factors constraining the growth of the market.

Key Market Trends

Therapeutics Segment is Expected to hold a Large Market Share Over the Forecast Period

Antithrombin can be used as therapeutics in conditions like cardiac surgeries, and in genetic condition like Antithrombin Deficiency. As per the data published by the American Society of Hematology 900,000 people in the United States develop blood clots yearly, and they are accountable for approximately 100,000 casualties each year.

Furthermore, according to the National Organisation for Rare Disorders, every one person in 3000 to 5000 people in the United States has Type I antithrombin deficiency. The increasing prevalence of blood clotting diseases increases the therapeutics and diagnostic usage of Antithrombin.

Asia-pacific region is Expected to be the Fastest Growing Region Over the Forecast Period

The Asia-pacific region is expected to show a high growth due to the developing nations such as India and China that are embracing new treatment procedures and techniques to combat various diseases. The increase in non-refundable incomes developing countries and their increasing capability to invest more money for advanced healthcare creates more opportunities for the market in the Asia Pacific. Although the occurrence of venous thromboembolism (VTE) in Asian populations is lesser than in Western countries, the total burden of VTE in Asia has been substantially underestimated. Factors that may explain the lower prevalence of VTE in Asian populations relative to Western populations comprise the incomplete availability of epidemiological data in Asia, ethnic differences in the genetic predilection to VTE, underdiagnoses, low awareness toward thrombotic disease, and possibly less symptomatic VTE in Asian patients. In recent years the awareness of the disease is increasing, raising the need for diagnosis and treatment.

Competitive Landscape

The antithrombin market is moderately competitive and consists of several major players. Some of the major market players are CSL Limited, Grifols SA, Takeda Pharmaceuticals, Octapharma AG, LFB USA, Axis-Shield Plc, Siemens AG, Thermo Fisher Scientific, and Lee Biosolutions Inc.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
レポート目次

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing coagulation diseases and open heart surgeries
4.2.2 Increasing usage of diagnostic kits using Antithrombin
4.3 Market Restraints
4.3.1 Alternative supplements
4.3.2 High Cost of Antithrombin therapy
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Usage
5.1.1 Therapeutics
5.1.2 Diagnostics
5.1.3 Research
5.1.4 Other
5.2 By Source
5.2.1 Human
5.2.2 Recombinant Goat milk
5.2.3 Others
5.3 By Type
5.3.1 Anticoagulant
5.3.2 Antiplatelet
5.3.3 Thrombolytic Drugs
5.4 By Route
5.4.1 Oral
5.4.2 Parenteral
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle-East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle-East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 CSL Limited
6.1.2 Grifols S.A
6.1.3 Takeda Pharmaceutical Company Limited
6.1.4 Octapharma AG
6.1.5 LFB USA
6.1.6 Axis-Shield Plc
6.1.7 Siemens AG
6.1.8 Thermo Fisher Scientific
6.1.9 Lee Biosolutions Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS